Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...
The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.
RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics. David W.
The following is a summary of “RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing,” published in the ...
Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...